Compare DexCom, Inc. (DXCM) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lennar Corporation — how do they compare? DexCom, Inc. trades at $84.02 (market cap $31.81B), while Lennar Corporation trades at $77.78 (market cap $18.10B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Lennar Corporation pays a 2.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lennar Corporation for 67 Days on average.
| DXCM | LEN | |
|---|---|---|
Market Cap | $31.81B | $18.10B |
Volume | 2,861,821 | 5,229,157 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $133.13 |
52-Week Low | $54.84 | $74.44 |
Typical Hold Time | 62 Days | 67 Days |
Enterprise Value | $31.26B | $22.52B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Lennar (LEN) trades at $77.60, showing modest daily gains amid bearish technical signals. The stock faces fundamental pressure with declining revenue and net income margins, though valuation metrics appear attractive with P/E of 14.42 and P/B below 1. Recent Q3 2026 earnings missed expectations, while Berkshire Hathaway's accumulating stake provides institutional support. Cash flow trends show operational challenges with negative net cash flow in 2025.
Investment outlook balances value opportunity against housing sector headwinds. The stock's below-book valuation and Berkshire's backing offer potential upside, but declining profitability and elevated mortgage rates pose significant risks. Analyst consensus leans cautiously optimistic with 46% buy ratings, though technical indicators suggest near-term bearish pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
